Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr. McFarland To Provide Clinical Update on trial - June 27
View:
Post by Eoganacht on Mar 31, 2022 12:11pm

Dr. McFarland To Provide Clinical Update on trial - June 27

Metals in Medicine
Gordon Research Conference

Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine

June 26 - July 1, 2022
 
Proctor Academy
204 Main Street
Andover, NH, United States

Monday 9:10 am - 9:35 am
Sherri McFarland (The University of Texas at Arlington, USA)
 
"Clinical Update on TLD1433, a Metallodrug Photosensitizer for Treating Non-Muscle Invasive Bladder Cancer with Photodynamic Therapy"
Comment by Mongoose1975 on Mar 31, 2022 12:24pm
If Sherri McFarland is making a Clinical Update at a conference June 27th. I imagine it's a good, scratch that....Excellent update because no one is going to speak at a conference if it's not. I also imagine we are going to get news long before that as I can't see her going up and saying "well it's a great therapy but we are still waiting for BTD" IMO
Comment by ScienceFirst on Mar 31, 2022 2:40pm
Prof. McFarland doesn't have access to data more than us as data must be made available to everyone at the same time, as she's not an employee of TLT and even there, it's only management that has access before anybody as they are under regulatory body disclosure rules.  She will use the latest data available. But June 27, that should be no problem for the data we're waiting ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250